TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00232791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher Select
Description: CYPHER SELECT™ Sirolimus-eluting Coronary Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher
Description: CYPHER™ Sirolimus-eluting Coronary Stent
Study: NCT01617226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine both arms; 75mg/m\^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine both arms; 75mg/m\^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
Study: NCT01610635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced versus standard intervals between blood donations
Description: Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced versus standard intervals between blood donations
Description: Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced versus standard intervals between blood donations
Description: Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
Study: NCT01305863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASC coated ePTFE vascular graft
Description: An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propaten graft
Description: 6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
Study: NCT01420484

Intervention type: OTHER
Intervention: different blood pressure intervals
Description: In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
Study: NCT02058147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/lixisenatide Fixed Ratio Combination
Description: Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide (AVE0010)
Description: Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
Study: NCT01617226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
Study: NCT03179904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denifanstat
Description: Given PO
Study: NCT02058147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration.
Study: NCT03840330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: High-intensity interval training group
Description: 16 weeks of High-intensity interval training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Moderate-intensity interval training group
Description: 16 weeks of Moderate-intensity interval training
Study: NCT02153567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 5mg daily will be given for the first 2 weeks and then Escitalopram 10mg daily will be given for the next 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for the next 10 weeks.
Study: NCT03836300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Infant Inter(X)action Intervention (PIXI)
Description: Psychoeducation around the diagnosed disorder, early development, and service navigation along with parent-child interaction activities, parent coaching, and family/parent well-being support.
Study: NCT01639872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
Study: NCT01046500

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: myo-inositol
Description: 2 grams twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: pill, 250 mg, twice a day
Study: NCT03603041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Participants in the protein arms will receive whey protein daily for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Participants in the protein arms will receive whey protein daily for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey protein
Description: Participants in the protein arms will receive whey protein daily for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.
Study: NCT01405053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rufinamide
Description: Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any other approved Antiepileptic Drug
Description: Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
Study: NCT02981069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Dapagliflozin
Study: NCT03459573

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts On Track
Description: Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts On Track
Description: Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts On Call
Description: Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts On Call
Description: Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts Revive
Description: Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts Revive
Description: Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
Study: NCT00804388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: 32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: 32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
Study: NCT03102229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Supportive Care - Status Checks
Description: Would occur everyday during treatment when a patient is deemed high-risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Supportive Care - Referrals
Description: On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
Study: NCT04178772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue Moist Multifocal Contact Lens JJVC Marketed Contact Lens
Description: JJVC Marketed Contact Lens
Study: NCT01889849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIP 48
Description: Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIP 48
Description: Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Study: NCT00887757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: 150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
Study: NCT02282969

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Interviews performed by study staff encompassing lung cancer screening and patient decision aids.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
Study: NCT01214785

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provision of household latrines
Description: WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
Study: NCT00067704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma writing

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Writing about daily events
Study: NCT03588377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Oximetry
Description: Intervention clusters:~On LHW's regular visits to households of their catchment area, they will daily screen for severe pneumonia and check oxygen level in blood using a pulse oximeter in all under \<5 children with symptoms of cough or difficulty breathing~Case definition:~1. Birth - 6 days: Fast breathing +/- Low oxygen in blood \<92% (Hypoxemia)~2. 7 days - 59 months: Fast breathing and/or Chest In-drawing + Any one danger sign: (Low oxygen in blood \<92% (Hypoxemia), Refusing to eat, Vomiting continuously, Convulsions, Lethargy/ Unconsciousness, Stridor.
Study: NCT04289896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercise
Description: The plyometric program to be followed by the subjects assigned to the experimental group during the four weeks includes: Squat jumps, alternate lunge, cyclic horizontal jump, horizontal left leg jump, horizontal right leg jump, vertical left leg jump, right leg vertical jump, squat box jumps, box jumps left leg, box jumps right leg, box to box squat jumps, box to box left leg, box to box right leg.~In all the exercises the subjects will be able to help themselves with the arms and a rest period of 120 seconds will be left between each series.~The intervention will be carried out prior to training, keeping a minimum of 48 hours of rest between sessions.
Study: NCT01916629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Photocil for Psoriasis
Description: Photocil for Psoriasis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sunscreen (SPF 2)
Description: Placebo - Sunscreen (SPF 2)
Study: NCT04538391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local ifiltration Bupivacaine, Meloxican and placebo
Description: no other intervention done

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local ifiltration Bupivacaine, Meloxican and placebo
Description: no other intervention done

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local ifiltration Bupivacaine, Meloxican and placebo
Description: no other intervention done
Study: NCT04591054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extended Vision IOL
Description: Vivity IOL implantation following cataract extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Aspheric Monofocal IOL
Description: enVista IOL implantation following cataract extraction
Study: NCT01751971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inspired oxygen (40%)
Description: Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Inspired oxygen (40%)
Description: Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Medical air with 21% oxygen via venturi mask (15 L/min).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Medical air with 21% oxygen via venturi mask (15 L/min).
Study: NCT01265680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
Study: NCT03856151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEALTHY BOX Powered heating pad (electronic moxibustion)
Description: Using heating pad (electronic moxibustion) with insulating materials on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEALTHY BOX Powered heating pad (electronic moxibustion)
Description: Using heating pad (electronic moxibustion) with insulating materials on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension
Study: NCT03773107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Irreversible proteasome inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Carfilzomib
Description: Irreversible proteasome inhibitor
Study: NCT01649947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~* Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv \< 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~* Diphenydramine 50 mg iv (or equivalent) \< 1 hour prior to paclitaxel infusion~* Ranitidine 50 mg iv \< 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~* Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv \< 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~* Diphenydramine 50 mg iv (or equivalent) \< 1 hour prior to paclitaxel infusion~* Ranitidine 50 mg iv \< 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Cohort 1 only:~Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles.
Study: NCT03811509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisphosphonate
Description: antiresorptives
Study: NCT01964235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 will be administered orally and continuously on a twice a day dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally and continuously on a twice a day dosing schedule.
Study: NCT01133171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Alone
Description: Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Alone
Description: Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard Plus Nurse
Description: Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
Study: NCT03179904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denifanstat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study: NCT01770600

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill administered daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riperidone
Description: 1 mg risperidone administered orally for 5 days
Study: NCT01128829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 60 ml of water were drank 10 min before doing a OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 60 ml of water were drank 10 min before doing a OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
Study: NCT03308396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Days 1-5 Dose 0: 60 mg/m\^2 Dose -1: 45 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Day 8 Durvalumab (1500 mg IV)